Overview of betrixaban and its role in clinical practice

@article{Lekura2018OverviewOB,
  title={Overview of betrixaban and its role in clinical practice},
  author={Jona Lekura and James S. Kalus},
  journal={American Journal of Health-System Pharmacy},
  year={2018},
  volume={75},
  pages={1095–1102}
}
Purpose. The role of betrixaban in the prevention of venous thromboembolism (VTE) in acutely medically ill patients and its efficacy and safety profiles are reviewed. Summary. Acutely medically ill patients have a high risk of developing VTE during hospitalization, and this risk continues into the postdischarge phase. Extended‐duration betrixaban therapy has been evaluated in a large clinical trial (the APEX trial) and in a meta‐analysis of pooled data on acutely medically ill patients. These… 
Direct oral anticoagulants: A new chapter in anticoagulation therapy
TLDR
Direct oral anticoagulants are now replacing VKAs and LMWH for many indications including stroke and systemic embolism prevention in nonvalvular atrial fibrillation, prevention, and treatment of venous thromboembolism and thromboprophylaxis following total knee/hip replacement surgery.
Systematic review of drug–drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management
TLDR
Most combinations of AC/AP agents and rifampin are problematic, and further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/ AP drugs.
Mechanisms of action of new oral coagulants
TLDR
The article presents the most frequent complications of anticoagulant therapy, as well as the mechanisms of action of specific and universal antidotes indicated for use in patients with life-threatening bleeding or in need of urgent surgery when using direct oral anticoAGulants.
Pathogenesis and management of heparin-induced thrombocytopenia and thrombosis.
Nová přímá perorální antikoagulancia - nové molekuly ve výzkumu
TLDR
V soucasne době nova přima peroralni antikoagulancia (DOAC) postupně nahrazuji dosavadni historicky nejcastěji uživaný warfarin, stejnĚ tak jako nove molekuly samotných antikoAGulancii.
Palladium-catalyzed Ugi-type reaction of 2-iodoanilines with isocyanides and carboxylic acids affording N-acyl anthranilamides.
TLDR
The first palladium-catalyzed Ugi-type multicomponent reaction for the synthesis of N-acyl anthranilamides from isocyanides, 2-iodoanilines and carboxylic acids has been developed and demonstrated by the late stage functionalization of two commercial drugs.
New direct oral anticoagulances - new molecules in research
V současné době nová přímá perorální antikoagulancia (DOAC) postupně nahrazují dosavadní historicky nejčastěji užívaný warfarin. Jedná se o dvě skupiny léčiv přímo inhibující faktor Xa (Xarelto,
A Review on the Use of Reversal Agents of Direct Oral Anticogulant Drugs in Case of Gastrointestinal Bleeding.
TLDR
Although these agents have been marketed for five years (idarucizumab) and two years (andexanet alfa) respectively, and despite guidelines considering antidotes as first-line agents in treating life-threatening hemorrhage when available, these antidotes seem to gain access very slowly in the clinical practice.

References

SHOWING 1-10 OF 25 REFERENCES
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)
TLDR
Among hospitalized medically ill patients, extended-duration betrixaban significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up, and among high-risk subjects, those with congestive heart failure or isChemic stroke as their index event, betrixabo significantly reduced the risk of stroke.
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
TLDR
In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis and reduced the risk of venous thromboembolism.
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
TLDR
In medically ill patients, an extended course of thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin and was associated with significantly more major bleeding events than was enoxAParin.
Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility
TLDR
Use of extended-duration enoxaparin reduces VTE more than it increases major bleeding events in acutely ill medical patients with level 1 immobility, those older than 75 years, and women.
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
TLDR
A definition of major bleeding in non‐surgical patients was developed that should be applicable to studies with all agents that interfere with hemostasis, including anticoagulants, platelet function inhibitors and fibrinolytic drugs.
Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
TLDR
Decisions regarding prophylaxis in nonsurgical patients should be made after consideration of risk factors for both thrombosis and bleeding, clinical context, and patients' values and preferences.
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
TLDR
A definition of major bleeding that should be applicable to all agents that interfere with hemostasis is developed and is to seek approval from the regulatory authorities to enhance its incorporation into future clinical trial protocols.
The epidemiology of venous thromboembolism
TLDR
Venous thromboembolism is a complex disease, involving interactions between acquired or inherited predispositions to thrombosis and VTE risk factors, including increasing patient age and obesity, hospitalization for surgery or acute illness, nursing-home confinement, active cancer, trauma or fracture, immobility or leg paresis, superficial vein thromBosis, and, in women, pregnancy and puerperium.
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
TLDR
Among patients with atrial fibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y12 inhibitor than amongThose who received triple therapy with warfarin, a P1Y12 inhibitors, and aspirin.
...
...